# US 7,608,696 B2 · IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,696 B2
- Document ID: US7608696B2
- Status: Granted
- Kind: B2
- Application number: 10/831,409
- Filed: 2004-04-23
- Published: 2004-11-11
- Granted: 2009-10-27
- Earliest claimed: 2001-10-26
- Assignees: Dana-Farber Cancer Institute, Inc.
- Inventors: Kornelia Polyak; Dale Porter
- Web page: https://patentgrep.com/patent/US7608696B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/57515: of the breast
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- Y10T 436/25: including sample preparation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of treating patients with invasive and metastatic breast cancer or degenerative neural conditions.

## Claims

### Claim 1

A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:6 (amino acids 43-64 of pro-IBC-1).

### Claim 2

A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:12 (amino acids 45-64 of pro-IBC-1).

### Claim 3

A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:7 (amino acids 53-64 of pro-IBC-1).

### Claim 4

A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:13 (amino acids 86-103 of pro-IBC-1).

### Claim 5 (depends on 1)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody is a chimerie antibody.

### Claim 6 (depends on 1)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody is a humanized antibody.

### Claim 7 (depends on 1)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 1, wherein the antigen-binding fragment is a single chain Fv fragment.

### Claim 8 (depends on 4)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 4, wherein the antibody is a chimeric antibody.

### Claim 9 (depends on 4)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 4, wherein the antibody is a humanized antibody.

### Claim 10 (depends on 4)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 4, wherein the antigen-binding fragment is a single chain Fv fragment.

### Claim 11 (depends on 2)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 2, wherein the antibody is a chimeric antibody.

### Claim 12 (depends on 2)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 2, wherein the antibody is a humanized antibody.

### Claim 13 (depends on 2)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 2, wherein the antigen-binding fragment is a single chain Fv fragment.

### Claim 14 (depends on 3)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 3, wherein the antibody is a chimeric antibody.

### Claim 15 (depends on 3)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 3, wherein the antibody is a humanized antibody.

### Claim 16 (depends on 3)

The monoclonal antibody, or antigen-binding fragment thereof, of claim 3, wherein the antigen-binding fragment is a single chain Fv fragment.